Global Short Bowel Syndrome (SBS) Market 2017-2021

Global short bowel syndrome (SBS) market overview

Market research analysts at Technavio predict that the global short bowel syndrome (SBS) market will grow steadily at a CAGR of around 26% by 2021. This market research analysis identifies the special drug designations as one of the primary growth factors for this market.  The market is dominated by few drugs and the special designation provides more potential for revenue generation and geographical expansion. The designation provides the vendors with benefits such as the extension of patent exclusivity period to address the need for an orphan drug, tax credits up to half of R&D costs, and exemption from US FDA application fees, consequently, reducing the vendors burden in developing a product for a rare disease. The R&D expenses are high for such novel molecules, as a result, a special designation encourages the vendors to conduct such R&D, which otherwise would make the molecule economically unviable.

The market research report identifies the increased awareness of gastrointestinal (GI) disorders as one of the key trends behind the growth of this market. Many government bodies, pharmaceutical companies, health ministries, and NGOs conduct health programs and camps to educate the people and raise awareness. Vendors distribute free samples and kits with the aim of educating the people and promoting their drugs. The increasing public awareness about the generic disorders or bowel related disorders is influencing the vendors and authorities to provide adequate knowledge and information to the segment with limited knowledge. The increasing awareness about the overall bowel health maintenance and remedial measures will benefit this niche market for SBS in terms of patient compliance and will increase sbs market revenue.

Competitive landscape and key vendors